NCT06835023

Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis

Recruiting now NA Last updated 20 February 2025

What this trial tests

NA trial testing Ringer lactate (RLS) in Acute Pancreatitis (AP) in 100 participants. Currently enrolling.

Timeline

10 January 2022

Primary endpoint
12 May 2025

12 May 2025

Quick facts

Lead sponsor	Satu Mare County Emergency Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	10 January 2022
Primary completion	12 May 2025
Estimated completion	12 May 2025
Sites	1 location across Romania

Drugs / interventions tested

• Ringer lactate (RLS) — full drug profile →
• Dextran+Ringer Lactat(D+RLS) — full drug profile →

Conditions studied

• Acute Pancreatitis (AP) — all drugs for Acute Pancreatitis (AP) →
• Acute Pancreatic Fluid Collection — all drugs for Acute Pancreatic Fluid Collection →
• Fluid Resuscitation — all drugs for Fluid Resuscitation →

Sponsor

Satu Mare County Emergency Hospital

Who can join

18 and older, any sex, with Acute Pancreatitis (AP) or Acute Pancreatic Fluid Collection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aims to learn if a combination of Dextran 40 and Ringer's lactate solution can improve fluid resuscitation in mild and moderate acute pancreatitis (AP) and prevent complications. The main questions it aims to answer are:

Does early fluid resuscitation with Dextran 40 plus Ringer's lactate improve patient outcomes compared to Ringer's alone? Does this treatment reduce inflammation, organ failure, and the need for intensive care unit (ICU) admission? Researchers will compare Dextran 40 plus Ringer's lactate to Ringer's alone to see if the combination therapy is more effective in reducing disease severity and complications.

Participants will:

Receive either Dextran 40 plus Ringer's lactate (1:3 ratio) or Ringer's lactate alone.

Have blood tests every 24 hours to measure inflammation and organ function. Be monitored for changes in disease severity, need for ICU admission, and hospitalization duration.

This study will help determine the best fluid resuscitation strategy for treating mild and moderate acute pancreatitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Fluid therapy strategies in acute pancreatitis: Randomized controlled trial comparing dextran and Ringer's lactate.
   Costea NC, Vesa S, Toma M, Pojoga C, et al · · 2025 · PMID 41357631 · DOI 10.4240/wjgs.v17.i11.109869